Global science and technology provider Danaher Corp. (NYSE: DHR – $103.06) and Integrated DNA Technologies (IDT) announced that Danaher has entered into a definitive agreement to acquire privately held IDT, a provider of nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics and pharmaceutical development. IDT’s primary business is the manufacturing of high-quality, custom DNA and RNA oligonucleotides. Founded in 1987, IDT has grown to become a leader in its served markets with more than 1,200 employees and over 100,000 customers worldwide. IDT will operate as a standalone operating company and brand within Danaher’s Life Sciences platform.
I continue to favor Washington, DC-based Danaher as a long-term play for the pull out to early next decade. Three to five-year capital appreciation potential provides the bulk of this appeal, while the small, but growing, dividend adds some additional total return potential.